Insights into the suanzaoren mechanism - From constructing the 3D structure of GABA-A receptor to its binding interaction analysis

Journal of the Chinese Institute of Chemical Engineers

Volumn 39, Issue 6, 2008, Pages 663-671

  Chen, Calvin Yu Chian ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Docking; Gamma aminobutyric acid; Jujubogenin; Molecular modeling; Suanzaoren

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BINS; BLOOD; DOCKING; HYDROGEN BONDS; MOLECULAR MODELING;

BINDING AFFINITIES; BINDING INTERACTION; BLOOD-BRAIN BARRIER; GAMMA-AMINOBUTYRIC ACIDS; JUJUBOGENIN; PROTEIN STRUCTURES; SUANZAOREN; THERAPEUTIC TARGETS;

BINDING SITES;

EID: 57649221020     PISSN: 03681653     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcice.2008.03.013     Document Type: Article

References (59)

1. Brejc, K., W. J. van Dijk, R. V. Klaassen, M. Schuurmans, J. van Der Oost, A. B. Smit, and T. K. Sixma, "Crystal Structure of an ACh-binding Protein Reveals the Ligand-binding Domain of Nicotinic Receptors," Nature, 411, 269 (2001).
2. Buhr, A. and E. Sigel, "A Point Mutation in the Gamma2 Subunit of Gamma-aminobutyric Acid Type A Receptors Results in Altered Benzodiazepine Binding Site Specificity," Proc. Natl. Acad. Sci. U.S.A., 94, 8824 (1997).
3. Chen, C. W., J. C. Lin, and H. L. Liu, "Molecular Dynamics Simulations of the Tetramerization Domain of Shaker and Kv1.1 Potassium Channels," J. Chin. Inst. Chem. Engrs., 36 (6), 649 (2005).
4. Chen, Y. C., "The Molecular Dynamic Simulation of Zolpidem Interaction with Gamma Aminobutyric Acid Type A Receptor," J. Chin. Chem. Soc., 54, 653 (2007).
5. Chen, Y. C. and Y. C. Chen, "Jujuboside A and Zolpidem Inhibiting the Gamma Aminobutyric Acid Type A Receptor," J. Biomech., S2 (40), 556 (2007a).
6. Chen, Y. C. and K. T. Chen, "Novel Selective Inhibitors of Hydroxyxanthone Derivatives for Human Cyclooxygenase-2," Acta Pharmacol. Sin., 28, 2027 (2007b).
7. Chen, K. T. and Y. C. Chen, "Xanthone Derivative Inhibitors for Human Cyclooxygenase-2 through Dynamic Performing," J. Biomech., S2 (40), 557 (2007c).
8. Chen, C. Y. C., "A Novel Perspective on Designing the Inhibitor of HER2 Receptor," J. Chin. Inst. Chem. Engrs., 39 (4), 291 (2008a).
9. Chen, C. Y. C., "Discovery of Novel Inhibitors for c-Met by Virtual Screening and Pharmacophore Analysis," J. Chin. Inst. Chem. Engrs., 39, 617 (2008b).
10. Chen, C. Y. C., "Inhibiting the Vascular Smooth Muscle Cells Proliferation by EPC and DPPC Liposomes Encapsulated Magnolol," J. Chin. Inst. Chem. Engrs., 39, 407 (2009c).
11. Chen, C. Y. C., Y. F. Chen, and H. Y. Tsai, "What is the Effective Component in Suanzaoren Decoction for Curing Insomnia? Discovery by Virtual Screening and Molecular Dynamic Simulation," J. Biomol. Struct. Dyn., 26, 57 (2008a).
12. Chen, C. Y. C., G. W. Chen, and W. Y. C. Chen, "Molecular Simulation of HER2/neu Degradation by HSP90 Inhibitors," J. Chin. Chem. Soc., 55, 297 (2008b).
13. Chou, K. C., K. D. Watenpaugh, and R. L. Heinrikson, "A Model of the Complex between Cyclin-dependent Kinase 5(Cdk5) and the Activation Domain of Neuronal Cdk5 Activator," Biochem. Biophys. Res. Commun., 259, 420 (1999).
14. Chou, K. C., D. Q. Wei, and W. Z. Zhong, "Binding Mechanism of Coronavirus Main Proteinase with Ligands and Its Implication to Drug Design against SARS," Biochem. Biophys. Res. Commun., 308, 148 (2003).
15. Chou, K. C., "Structural Bioinformatics and Its Impact to Biomedical Science," Curr. Med. Chem., 11, 2105 (2004a).
16. Chou, K. C., "Modelling Extracellular Domains of GABA-A Receptors: Subtypes 1, 2, 3, and 5," Biochem. Biophys. Res. Commun., 316, 636 (2004b).
17. Chou, K. C., D. Q. Wei, Q. S. Du, S. Sirois, and W. Z. Zhong, "Progress in Computational Approach to Drug Development against SARS," Curr. Med. Chem., 13, 3263 (2006).
18. Chung, K. F. and C. K. Lee, "Over-the-counter Sleeping Pills: A Survey of Use in Hong Kong and a Review of Their Constituents," Gen. Hosp. Psychiatry., 24, 430 (2002).
19. Ci, S. Q., T. R. Ren, C. X. Ma, and Z. G. Su, "Modeling of αk/γ2 (k = 1, 2, 3 and 5) Interface of GABA(A) Receptor and Docking Studies with Zolpidem: Implications for Selectivity," J. Mol. Graph. Model., 26, 537 (2007).
20. Du, Q., S. Wang, Z. Jiang, W. Gao, Y. Li, D. Wei, and K. C. Chou, "Application of Bioinformatics in Search for Cleavable Peptides of SARS-CoV M(pro) and Chemical Modification of Octapeptides," Med. Chem., 1, 209 (2005a).
21. Du, Q., S. Wang, D. Wei, S. Sirois, and K. C. Chou, "Molecular Modeling and Chemical Modification for Finding Peptide Inhibitor against Severe Acute Respiratory Syndrome Coronavirus Main Proteinase," Anal. Biochem., 337, 262 (2005b).
22. Du, Q. S., H. Sun, and K. C. Chou, "Inhibitor Design for SARS Coronavirus Main Protease Based on "Distorted Key Theory"," Med. Chem., 3, 1 (2007).
23. Ernst, M., D. Brauchart, S. Boresch, and W. Sieghart, "Comparative Modeling of GAEA(A) Receptors: Limits, Insights, Future Developments," Neuroscience, 119, 933 (2003).
24. Falco, J. L., M. Pique, M. Gonzalez, I. Buira, E. Mendez, J. Terencio, C. Perez, M. Princep, A. Palomer, and A. Guglietta, "Synthesis, Pharmacology and Molecular Modeling of N-Substituted 2-Phenyl-Indoles and Benzimidazoles as Potent GABA(A) Agonists," Eur. J. Med. Chem., 41, 985 (2006).
25. Gao, W. N., D. Q. Wei, Y. Li, H. Gao, W. R. Xu, A. X. Li, and K. C. Chou, "Agaritine and Its Derivatives are Potential Inhibitors against HIV Proteases," Med. Chem., 3, 221 (2007).
26. Gehlhaar, D. K., G. M. Verkhivker, P. A. Rejto, C. J. Sherman, D. B. Fogel, L. J. Fogel, and S. T. Freer, "Molecular Recognition of the Inhibitor AG-1343 by HIV-1 Protease: Conformationally Flexible Docking by Evolutionary Programming," Chem. Biol., 2, 317 (1995).
27. Guo, X. L., L. Li, D. Q. Wei, Y. S. Zhu, and K. C. Chou, "Cleavage Mechanism of the H5N1 Hemagglutinin by Trypsin and Furin," Amino Acids, 35, 375 (2008).
28. Hirouchi, M., J. Taguchi, T. Ueha, and K. Kuriyama, "GABA-stimulated 36Cl-Influx into Reconstituted Vesicles with Purified GABAA/ Benzodiazepine Receptor Complex," Biochem. Biophys. Res. Commun., 146, 1471 (1987).
29. Jones, B. L., P. J. Whiting, and L. P. Henderson, "Mechanisms of Anabolic Androgenic Steroid Inhibition of Mammalian Epsilon-subunit-containing GABAA Receptors," J. Physiol., 573, 571 (2006).
30. A) Receptor," Biochem. Soc. Trans., 32, 540 (2004).
31. Klausberger, T., K. Fuchs, B. Mayer, N. Ehya, and W. Sieghart, "GABA(A) Receptor Assembly Identification and Structure of γ(2) Sequences Forming the Intersubunit Contacts with α(1) and β(3) Subunits," J. Biol. Chem., 275, 8921 (2000).
32. 2+-Binding Sites," Proc. Natl. Acad. Sci. U.S.A., 99, 3210 (2002).
33. Lee, J. Y., J. S. Choi, C. H. Ahn, I. S. Kim, J. H. Ha, and C. J. Jeon, "Calcium-binding Protein Calretinin Immunoreactivity in the Dog Superior Colliculus," Acta Histochem. Cytochem., 39, 125 (2006).
34. Li, L., D. Q. Wei, J. F. Wang, and K. C. Chou, "Computational Studies of the Binding Mechanism of Calmodulin with Chrysin," Biochem. Biophys. Res. Commun., 358, 1102 (2007a).
35. Li, Y., D. Q. Wei, W. N. Gao, H. Gao, B. N. Liu, C. J. Huang, W. R. Xu, D. K. Liu, H. F. Chen, and K. C. Chou, "Computational Approach to Drug Design for Oxazolidinones as Antibacterial Agents," Med. Chem., 3, 576 (2007b).
36. Liao, J. F., Y. M. Jan, S. Y Huang, H. H. Wang, L. L. Yu, and C. F. Chen, "Evaluation with Receptor Binding Assay on the Water Extracts of Ten CNS-active Chinese Herbal Drugs," Proc. Natl. Sci. Counc. Repub. China. B, 19, 151 (1995).
37. Liu, H. L. and W. C. Hsieb, "Molecular Dynamics for Thermal Unfolding Behaviors of N-Carbamyl-D-Amino Acid Amidohydrolase," J. Chin. Inst. Chem. Engrs., 36, 285 (2005).
38. Muegge, I. and Y. C. Martin, "A General and Fast Scoring Function for Protein-ligand Interactions: A Simplified Potential Approach," J. Med. Chem., 42, 791 (1999).
39. Rowlett, J. K., D. M. Platt, S. Lelas, J. R. Atack, and G. R. Dawson, "Different GABAA Receptor Subtypes Mediate the Anxiolytic, Abuse-related, and Motor Effects of Benzodiazepine-like Drugs in Primates," Proc. Natl. Acad. Sci. U.S.A., 102, 915 (2005).
40. Sancar, F., S. S. Ericksen, A. M. Kucken, J. A. Teissere, and C. Czajkowski, "Structural Determinants for High-affinity Zolpidern Binding to GABA-A Receptors," Mol. Pharmacol., 71, 38 (2007).
41. Shou, C. H., J. Wang, X. X. Zheng, and D. W. Goo, "Inhibitory Effect of Jujuboside A on Penicillin Sodium Induced Hyperactivity in Rat Hippocampal CA1 Area In Vitro," Acta Pharmacol. Sin., 22, 986 (2001).
42. A Receptors," Trends Pharmacol. Sci., 18, 425 (1997).
43. A Receptors," Biochem. J., 310 (Pt 1), 1 (1995).
44. Venkatachalam, C. M., X. Jiang, T. Oldfield, and M. Waldman, "LigandFit: A Novel Method for the Shape-directed Rapid Docking of Ligands to Protein Active Sites," J. Mol. Graph. Model., 21, 289 (2003).
45. Wang, J. F., D. Q. Wei, L. Li, S. Y. Zheng, Y. X. Li, and K. C. Chou, "3D Structure Modeling of Cytochrome P450 2C19 and Its Implication for Personalized Drug Design," Biochem. Biophys. Res. Commun., 355, 513 (2007a).
46. Wang, J. F., D. Q. Wei, Y. Lin, Y. H. Wang, H. L. Du, Y. X. Li, and K. C. Chou, "Insights from Modeling the 3D Structure of NAD(P)H-dependent D-Xylose Reductase of Pichia stipitis and Its Binding Interactions with NAD and NADP," Biochem. Biophys. Res. Commun., 359, 323 (2007b).
47. Wang, S. Q., Q. S. Du, K. Zhao, A. X. Li, D. Q. Wei, and K. C. Chou, "Virtual Screening for Finding Natural Inhibitor against Cathepsin-L for SARS Therapy," Amino Acids, 33, 129 (2007c).
48. Wang, J. F., D. Q. Wei, C. Chen, Y. Li, and K. C. Chou, "Molecular Modeling of Two CYP2C19 SNPs and Its Implications for Personalized Drug Design," Protein Pept. Lett., 15, 27 (2008).
49. Wei, D. Q., S. Sirois, Q. S. Du, H. R. Arias, and K. C. Chou, "Theoretical Studies of Alzheimer's Disease Drug Candidate 3-[(2,4-dimethoxy)benzylidene]-Anabaseine (GTS-21) and Its Derivatives," Biochem. Biophys. Res. Commun., 338, 1059 (2005).
50. Wei, D. Q., Q. S. Du, H. Sun, and K. C. Chou, "Insights from Modeling the 3D Structure of H5N1 Influenza Virus Neuraminidase and Its Binding Interactions with Ligands," Biochem. Biophys. Res. Commun., 344, 1048 (2006a).
51. Wei, D. Q., R. Zhang, Q. S. Du, W. N. Gao, Y. Li, H. Gao, S. Q. Wang, X. Zhang, A. X. Li, S. Sirois, and K. C. Chou, "Anti-SARS Drug Screening by Molecular Docking," Amino Acids, 31, 73 (2006b).
52. Wei, H., R. Zhang, C. Wang, H. Zheng, A. Li, K. C. Chou, and D. Q. Wei, "Molecular Insights of SAH Enzyme Catalysis and Implication for Inhibitor Design," J. Theor. Biol., 244, 692 (2007).
53. Yi, P. L., C. H. Tsai, Y. C. Chen, and F. C. Chang, "γ-aminobutyric Acid (GABA) Receptor Mediates Suanzaorentang, a Traditional Chinese Herb Remedy-induced Sleep Alteration," J. Biomed. Sci., 14, 285 (2007).
54. Zhang, J,, C. H. Luan, K. C. Chou, and G. V. Johnson, "Identification of the N-terminal Functional Domains of Cdk5 by Molecular Truncation and Computer Modeling," Proteins, 48, 447 (2002).
55. Zhang, X., J. Gureasko, K. Shen, P. A. Cole, and J. Kuriyan, "An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor," Cell, 125, 1137 (2006).
56. Zhao, J., S. P. Li, F. Q. Yang, P. Li, and Y. T. Wang, "Simultaneous Determination of Saponins and Fatty Acids in Ziziphus jujuba (Suanzaoren) by High Performance Liquid Chromatography-Evaporative Light Scattering Detection and Pressurized Liquid Extraction," J. Chromatogr. A, 1108, 188 (2006).
57. Zheng, H., D. Q. Wei, R. Zhang, C. Wang, H. Wei, and K. C. Chou, "Screening for New Agonists against Alzheimer's Disease," Med. Chem., 3, 488 (2007).
58. Zhou, G. P. and F. A. 2nd Troy, "NMR Studies on How the Binding Complex of Polyisoprenol Recognition Sequence Peptides and Polyisoprenols Can Modulate Membrane Structure," Curr. Protein Pept. Sci., 6, 399 (2005a).
59. Zhou, G. P. and F. A. 2nd Troy, "NMR Study of the Preferred Membrane Orientation of Polyisoprenols (dolichol) and the Impact of their Complex with Polyisoprenyl Recognition Sequence Peptides on Membrane Structure," Glycobiology, 15, 347 (2005b).